Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor

Surgery for Obesity and Related Diseases

Volumn 12, Issue 6, 2016, Pages 1236-1242

  Holst, Jens Juul ^a   Madsbad, Sten ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Exendin 9 39; GLP 1receptor antagonists; Glucagon like peptide 1; Peptide YY; PYY; Reactive hypoglycemia; Roux en Y gastric bypass; RYGB

Indexed keywords

EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PROGLUCAGON; UNCLASSIFIED DRUG; BILE ACID; EXENDIN 9; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 2; PEPTIDE FRAGMENT;

ANTIDIABETIC ACTIVITY; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; GASTRIC BYPASS SURGERY; GLUCOSE TOLERANCE; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTOPERATIVE PERIOD; POSTPRANDIAL STATE; PRIORITY JOURNAL; REMISSION; REVIEW; SLEEVE GASTRECTOMY; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; INTESTINE ABSORPTION; METABOLISM; MOUSE; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS);

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GASTRIC BYPASS; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INSULIN; INTESTINAL ABSORPTION; MICE; OBESITY; PEPTIDE FRAGMENTS; REMISSION INDUCTION;

EID: 84995380335     PISSN: 15507289     EISSN: 18787533     Source Type: Journal    
DOI: 10.1016/j.soard.2016.02.033     Document Type: Review

References (68)

1. [1] Patti, M.E., McMahon, G., Mun, E.C., et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:11 (2005), 2236–2240.
2. [2] Korner, J., Bessler, M., Inabnet, W., Taveras, C., Holst, J.J., Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3:6 (2007), 597–601.
3. [3] Goldfine, A.B., Mun, E.C., Devine, E., et al. Patients with neuroglycopenia post gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 92:12 (2007), 4678–4685.
4. [4] Pories, W.J., Swanson, M.S., MacDonald, K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:3 (1995), 339–350.
5. [5] Dirksen, C., Jorgensen, N.B., Bojsen-Moller, K.N., et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) 37:11 (2013), 1452–1459.
6. [6] Le Roux, C.W., Aylwin, S.J., Batterham, R.L., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:1 (2006), 108–114.
7. [7] Le Roux, C.W., Welbourn, R., Werling, M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:5 (2007), 780–785.
8. [8] Holst, J.J., Orskov, C., Nielsen, O.V., Schwartz, T.W., Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:2 (1987), 169–174.
9. [9] Vilsboll, T., Knop, F.K., Krarup, T., et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88:10 (2003), 4897–4903.
10. [10] Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:9309 (2002), 824–830.
11. [11] Aaboe, K., Knop, F.K., Vilsboll, T., et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12:4 (2010), 323–333.
12. [12] Verdich, C., Flint, A., Gutzwiller, J.P., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:9 (2001), 4382–4389.
13. [13] Secher, A., Jelsing, J., Baquero, A.F., et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124:10 (2014), 4473–4488.
14. [14] Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:1 (2015), 11–22.
15. [15] Flint, A., Raben, A., Astrup, A., Holst, J.J., Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:3 (1998), 515–520.
16. [16] Rehfeld, J.F., Heding, L.G., Holst, J.J., Increased gut glucagon release as pathogenetic factor in reactive hypoglycaemia?. Lancet 1:795 (1973), 116–118.
17. [17] Holst, J.J., Christiansen, J., Kuhl, C., The enteroglucagon response to intrajejunal infusion of glucose, triglycerides, and sodium chloride, and its relation to jejunal inhibition of gastric acid secretion in man. Scand J Gastroenterol 11:3 (1976), 297–304.
18. [18] Holst, J.J., Extrapancreatic glucagons. Digestion 17:2 (1978), 168–190.
19. [19] Holst, J.J., Sorensen, T.I., Andersen, A.N., et al. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol 14:2 (1979), 205–207.
20. [20] Kellum, J.M., Kuemmerle, J.F., O'Dorisio, T.M., et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 211:6 (1990), 763–770.
21. [21] Baldissera, F.G., Holst, J.J., Knuhtsen, S., Hilsted, L., Nielsen, O.V., Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 21:1-2 (1988), 151–166.
22. [22] Schjoldager, B.T., Baldissera, F.G., Mortensen, P.E., Holst, J.J., Christiansen, J., Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18:5 (1988), 499–503.
23. [23] Krarup, T., Immunoreactive gastric inhibitory polypeptide. Endocr Rev 9:1 (1988), 122–134.
24. [24] Miholic, J., Orskov, C., Holst, J.J., Kotzerke, J., Meyer, H.J., Emptying of the gastric substitute, glucagon-like peptide-1 (GLP- 1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36:10 (1991), 1361–1370.
25. [25] Toft-Nielsen, M., Madsbad, S., Holst, J.J., Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41:10 (1998), 1180–1186.
26. [26] Vilsboll, T., Krarup, T., Madsbad, S., Holst, J.J., No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 18:2 (2001), 144–149.
27. [27] Madsbad, S., Dirksen, C., Holst, J.J., Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2:2 (2014), 152–164.
28. [28] Dirksen, C., Hansen, D.L., Madsbad, S., et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care 33:2 (2010), 375–377.
29. [29] Jacobsen, S.H., Olesen, S.C., Dirksen, C., et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 22:7 (2012), 1084–1096.
30. [30] Deacon, C.F., Johnsen, A.H., Holst, J.J., Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:3 (1995), 952–957.
31. [31] Kuhre, R.E., Wewer Albrechtsen, N.J., Hartmann, B., Deacon, C.F., Holst, J.J., Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. J Diabetes Complications 29:3 (2015), 445–450.
32. [32] Holst, J.J., Deacon, C.F., Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:4 (2005), 612–615.
33. [33] Hjollund, K.R., Deacon, C.F., Holst, J.J., Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 54:8 (2011), 2206–2208.
34. [34] Holst, J.J., Glucagon and glucagon-like peptides 1 and 2. Results Probl Cell Differ 50 (2010), 121–135.
35. [35] Rhee, N.A., Wahlgren, C.D., Pedersen, J., et al. Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia 58:10 (2015), 2254–2258.
36. [36] Falken, Y., Hellstrom, P.M., Holst, J.J., Naslund, E., Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96:7 (2011), 2227–2235.
37. [37] Schmidt, J.B., Pedersen, S.D., Gregersen, N.T., et al. Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial. Int J Obes (Lond) 40:2 (2013), 281–290.
38. [38] Batterham, R.L., Heffron, H., Kapoor, S., et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4:3 (2006), 223–233.
39. [39] Dirksen, C., Damgaard, M., Bojsen-Moller, K.N., et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol Motil, 25(4), 2013, 346 e255.
40. [40] Jacobsen, S.H., Bojsen-Moller, K.N., Dirksen, C., et al. Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. Diabetologia 56:10 (2013), 2250–2254.
41. [41] Schmidt, J.B., Gregersen, N.T., Pedersen, S.D., et al. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab 306:11 (2014), E1248–E1256.
42. [42] Troy, S., Soty, M., Ribeiro, L., et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 8:3 (2008), 201–211.
43. [43] Saeidi, N., Meoli, L., Nestoridi, E., et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 341:6144 (2013), 406–410.
44. [44] Bojsen-Moller, K.N., Jacobsen, S.H., Dirksen, C., et al. Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. Am J Clin Nutr 102:3 (2015), 600–607.
45. [45] Lutz, T.A., Bueter, M., The physiology underlying Roux-en-Y gastric bypass: a status report. Am J Physiol Regul Integr Comp Physiol 307:11 (2014), R1275–R1291.
46. [46] Kuhre, R.E., Frost, C.R., Svendsen, B., Holst, J.J., Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine. Diabetes 64:2 (2015), 370–382.
47. [47] Gribble, F.M., Reimann, F., Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol 78 (2016), 277–299.
48. [48] Naslund, E., Backman, L., Holst, J.J., Theodorsson, E., Hellstrom, P.M., Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8:3 (1998), 253–260.
49. [49] Jorgensen, N.B., Jacobsen, S.H., Dirksen, C., et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 303:1 (2012), E122–E131.
50. [50] Hansen, E.N., Tamboli, R.A., Isbell, J.M., et al. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol 300:5 (2011), G795–G802.
51. [51] Jorgensen, N.B., Dirksen, C., Holst, J.J., Madsbad, S., Gastric bypass and duodenal and gastric feeding: a comment to Hansen et al. Am J Physiol Gastrointest Liver Physiol 301:5 (2011), G938–G939.
52. [52] Jorgensen, N.B., Dirksen, C., Bojsen-Moller, K.N., et al. Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after roux-en-y gastric bypass in patients with type 2 diabetes. Diabetes 62:9 (2013), 3044–3052.
53. [53] Salehi, M., Prigeon, R.L., D׳Alessio, D.A., Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 60:9 (2011), 2308–2314.
54. [54] Bojsen-Moller, K.N., Dirksen, C., Jorgensen, N.B., et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63:5 (2014), 1725–1737.
55. [55] Isbell, J.M., Tamboli, R.A., Hansen, E.N., et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 33:7 (2010), 1438–1442.
56. [56] Edelman, S., Ng-Mak, D.S., Fusco, M., et al. Control of type 2 diabetes after 1 year of laparoscopic adjustable gastric banding in the helping evaluate reduction in obesity (HERO) study. Diabetes Obes Metab 16:10 (2014), 1009–1015.
57. [57] Romero, F., Nicolau, J., Flores, L., et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc 26:8 (2012), 2231–2239.
58. [58] Trung, V.N., Yamamoto, H., Furukawa, A., et al. Enhanced intestinal motility during oral glucose tolerance test after laparoscopic sleeve gastrectomy: preliminary results using cine magnetic resonance imaging. PLoS One, 8(6), 2013, e65739.
59. [59] Patti, M.E., Houten, S.M., Bianco, A.C., et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17:9 (2009), 1671–1677.
60. [60] Ryan, K.K., Tremaroli, V., Clemmensen, C., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:7499 (2014), 183–188.
61. [61] Jorgensen, N.B., Dirksen, C., Bojsen-Moller, K.N., et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab 100:3 (2015), E396–E406.
62. [62] Sonne, D.P., Lund, A., Faber, J., Holst, J.J., Vilsboll, T., Knop, F.K., On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. Endocr Connect 3:4 (2014), 193–199.
63. [63] Odstrcil, E.A., Martinez, J.G., Santa Ana, C.A., et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 92:4 (2010), 704–713.
64. [64] Salehi, M., Gastaldelli, A., D׳Alessio, D.A., Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 146:3 (2014), 669–680.
65. [65] McLaughlin, T., Peck, M., Holst, J., Deacon, C., Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 95:4 (2010), 1851–1855.
66. [66] Service, G.J., Thompson, G.B., Service, F.J., Andrews, J.C., Collazo-Clavell, M.L., Lloyd, R.V., Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353:3 (2005), 249–254.
67. [67] Dirksen, C., Bojsen-Moller, K.N., Jorgensen, N.B., et al. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 56:12 (2013), 2679–2687.
68. [68] Martinussen, C., Bojsen-Moller, K.N., Dirksen, C., et al. Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. Am J Physiol Endocrinol Metab 308:6 (2015), E535–E544.